Mary Elizabeth Patti, MD
Endocrinology, Diabetes & Metabolism · Boston, MANPI 1386681070
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,913 of the $1,994 with a category attached, or 95.9%. Recordati_rare_diseases_inc. accounts for 95.9% of it on its own, with 1 other manufacturer making up the rest.
Across 2 payments — averaging $997.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Recordati_rare_diseases_inc.$2K
- Covidien LP$81
Across 27 payments — averaging $18,086 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Recordati_rare_diseases_inc.$448K
- Dexcom, Inc.$33K
- Xeris Pharmaceuticals, Inc.$8K
What the payments were for
- Consulting fees$1,91396%
- Food & beverage$814%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Recordati_rare_diseases_inc. | 1 | $1,913 |
| Covidien LP | 1 | $81 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ISTURISA$1,913
How this compares
$1,994 in reported general payments places this provider in the 65th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
See all endocrinology, diabetes & metabolism providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 81 | $115,612 |
| TrulicityDulaglutide | 40 | $61,904 |
| Gvoke Hypopen 2-PackGlucagon | 42 | $39,820 |
| Diazoxide | 50 | $37,322 |
| MounjaroTirzepatide | 17 | $29,140 |
| JardianceEmpagliflozin | 14 | $18,282 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 25 | $15,665 |
| Octreotide Acetate | 13 | $9,578 |
| Zegalogue AutoinjectorDasiglucagon Hcl | 15 | $9,066 |
| TradjentaLinagliptin | 14 | $7,359 |
| BaqsimiGlucagon | 15 | $5,812 |
| Acarbose | 51 | $3,229 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 18 | $1,725 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 13 | $1,544 |
| Ultra-Fine Micro Pen NeedlePen Needle, Diabetic | 15 | $883 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Boston
- Jason GagliaBoston$2.4M
- Vanita ArodaBoston$482K
- Michael RosenblattBoston$447K
- Steven RussellBoston$445K
- Beverly BillerBoston$346K
- Christos MantzorosBoston$243K
- Augusto Caballero-RoblesBoston$150K
- Osama HamdyBoston$117K
- Barbara KahnBoston$105K
- Naomi FisherBoston$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.